USNA

USANA Health Sciences Inc. - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 29, 2024. USANA Health Sciences, Inc. is a global direct-selling company developing and manufacturing science-based nutritional and personal care products. The company operates primarily through two geographic regions: Asia Pacific (including Greater China, Southeast Asia Pacific, and North Asia) and Americas and Europe. As of the period end, the company reported approximately 468,000 active customers worldwide.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 10.6% in Q2 2024 compared to Q2 2023. This was driven by a decrease in active customers and lower average spend per customer, partially offset by modest price increases. Unfavorable currency exchange rates negatively impacted sales by an estimated $5.3 million.
• Profitability Compression: Net earnings fell 39.7% year-over-year due to lower sales volume, higher relative operating expenses, and an increased effective tax rate (48.4% in Q2 2024 vs. 35.5% in Q2 2023).
• Regional Performance:
  • Asia Pacific: Sales declined 11.9% (constant currency decline of 9.2%). Significant declines were noted in South Korea (-19.3% local currency) and the Philippines (-28.8% local currency). China sales declined 8.3% in local currency due to lower average spend.
  • Americas and Europe: Sales declined 5.3% (constant currency decline of 5.0%). The U.S. market saw a 10.3% decline driven by fewer active customers and lower spend.
• Customer Base: Total active customers decreased by 3.9% to 468,000. North Asia saw the largest percentage drop in active customers (-17.6%).

Guidance, Outlook, and Risks

Management Commentary: Management attributes the decline in sales to a reduction in active customers and average spend, noting that currency headwinds exacerbated the reported decline. Gross margins were maintained through lower material costs and freight charges, offsetting the loss of leverage on lower sales. The company continues to focus on increasing the number of active customers.

Capital Allocation: The company repurchased and retired 194,000 shares for approximately $9.5 million during the first six months of 2024. As of June 29, 2024, $61.7 million remains authorized for future share repurchases.

Risks and Contingencies:

• Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of June 29, 2024, due to material weaknesses in information technology general controls (ITGCs). Remediation efforts are ongoing, with completion expected prior to the end of fiscal year 2024.
• China Operations: Significant exposure to China (approx. 50% of sales) introduces risks related to regulatory changes, data privacy laws, and restrictions on remitting profits to the U.S.
• Direct Selling Model: Dependence on independent Associates and regulatory scrutiny of the direct selling model in various jurisdictions.

Investor Verification Checklist

• Customer Trends: Verify the trajectory of active customer counts and average spend per customer, particularly in key markets like China, South Korea, and the U.S.
• IT Remediation: Monitor progress on the remediation of material weaknesses in IT general controls and the timeline for restoring effective internal controls.
• Currency Impact: Assess the sensitivity of future earnings to foreign exchange rate fluctuations, given that 90.1% of sales are generated outside the U.S.
• Tax Rate Volatility: Review the drivers of the elevated effective tax rate (43.0% YTD) and its sustainability.
• Share Repurchase Activity: Track the utilization of the remaining $61.7 million repurchase authorization and its impact on liquidity.